Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026
Key Highlights
- ➤Biomea Fusion (BMEA) will present Phase 1 BMF-650 clinical results at ObesityWeek 2026
- ➤BMF-650 is an investigational next-generation oral small molecule GLP-1 receptor agonist
- ➤Poster presentation scheduled November 16, 2026, at 2:30 p.m. ET
- ➤Thorsten A. Kirschberg, Ph.D., will present the first-in-human study results
SAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on diabetes and obesity, today announced that it will present Phase 1 clinical results for BMF-650, its investigational next-generation oral small molecule GLP-1 receptor agonist, at ObesityWeek(®) 2026. The conference will take place November 14–17, 2026, at the Gaylord National Resort & Convention Center in National Harbor, Maryland.
Presentation Details Title: First-In-Human Study Results for BMF-650 a Small Molecule Oral GLP-1 Receptor Agonist Session: Obesity-Related Complications & Multimorbidity Poster Number: Poster 828 Presenter: Thorsten A. Kirschberg, Ph.D. Session Date/Time: Monday, November 16, 2026, at 2:30 p.m. – 3:30 p.m. ET
Get started
Create a free account to read the full story.